K223101 is an FDA 510(k) clearance for the BD Secondary Infusion Set. Classified as Set, Administration, Intravascular (product code FPA), Class II - Special Controls.
Submitted by Care Fusion (San Diego, US). The FDA issued a Cleared decision on May 12, 2023 after a review of 224 days - an extended review cycle.
This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5440 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.
View all Care Fusion devices